Exclusive accelerated approval drugs comprise ‘relatively small share’ of Medicare spending

Regulatory NewsRegulatory NewsBiologics/ biosimilars/ vaccinesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy